Phase 3Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 14,012 enrolled
- Conditions
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL; Placebo in 1.5ml
- Ages
- adults, older adults
- Registry
- NCT05739383
Full record on ClinicalTrials.gov
From the registry
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
Primary outcomes
- Time to the first occurrence of 4P-MACE
History
Primary completion expected
Last registry update
Started
Registered